Edesa Biotech, Inc. carries no debt; cash flow comfortably covers obligations.

Edesa Biotech, Inc.'s free cash flow has decreased 49.73% from $-4.89M last year to $-7.32M, signaling decreasing performance

Edesa Biotech, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Edesa Biotech, Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.00 today, signaling strengthened financials

Edesa Biotech, Inc. has a net cash position, so leverage is healthy.

Edesa Biotech, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Edesa Biotech, Inc. has insufficient data to evaluate this check.

Edesa Biotech, Inc.'s short-term assets of $11.51M exceed its short-term liabilities of $1.08M

Edesa Biotech, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Edesa Biotech, Inc.'s return on equity of -82.34%, is lower than 15.00%, indicating bad performance

Edesa Biotech, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Edesa Biotech, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Edesa Biotech, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Edesa Biotech, Inc. has negative free cash flow, indicating cash burn

Edesa Biotech, Inc.'s yearly earnings has decreased 16.46% since last year from $-6.17M to $-7.19M, signaling decreasing performance

Edesa Biotech, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -108.00% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Edesa Biotech, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Edesa Biotech, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Edesa Biotech, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Edesa Biotech, Inc. has insufficient data to evaluate this check.

Edesa Biotech, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Edesa Biotech, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Edesa Biotech, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Edesa Biotech, Inc. has insufficient data to evaluate this check.

Edesa Biotech, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Edesa Biotech, Inc. has a price-to-book ratio of 4.24x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Edesa Biotech, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue